New

Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Providers›iShares›XDNA
ETF screener

XDNA ETF · iShares Genomics Immunology and Healthcare Index ETF

The XDNA Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: NYSE FactSet Global Genomics and Immuno Biopharma Index. The XDNA ETF provides physical exposure, so by buying it you actually own parts of all the 50 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 5/1/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofWorld Blended Cap1M perf.+10.99%
Last price
$41.22
1M perf.
-1.53%
1M flows
+€687K
AuM
€4.5M
E/R
0.44%
Rating
ESG Consensus®
esg grade icon
XDNA
$41.22

Performance & flows

Segment for quartile rank
February 2, 2026 → May 1, 2026
0-8-6-4-202468%MARAPRMAYMARAPRMAY
Create a free account to view the flows graph
XDNA
$41.25
+0.92%
World Blended Cap
+4.89%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
-1.53%
icon
+0.92%
icon
+40.26%
icon
+27.46%
icon
N/A
-0.50%
-0.52%
+10.98%
icon
Flows

Key fund info

Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) Â· 
Main characteristics
Issuer
CUSIP
46437W105
ISIN
CA46437W1059
AuM
€4.5M
icon
E/R
0.44%
icon
Replication rating
icon
ESG Consensus®
esg grade icon
icon
More details
NAV
5/1/2026
$41.25
1D NAV change
-0.50%
Dividend policy
Replication method
Direct (Physical)
Replication model
Optimized sampling
No. of holdings
50
Inception date
4/26/2022
Jurisdiction
Canada
Distribution
Canada
Legal structure
Unit Trust
Base currency
CAD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The ETF has been designed to provide investors with exposure to the performance of an index, selected at the discretion of BlackRock, that is composed of companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. The current index for the ETF is the NYSE FactSet Global Genomics and Immuno Biopharma Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Similar ETFs in your region

IDNA
1M perf.
+0.64%
E/R
0.47%
2B78
1M perf.
-2.43%
E/R
0.4%
LIV
1M perf.
-2.27%
E/R
0.75%
HTEC
1M perf.
+4.94%
E/R
0.8%
PJP
1M perf.
+0.84%
E/R
0.57%

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
+0.92%
icon
+40.26%
icon
+27.46%
icon
N/A
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
63.18%
France
8.83%
Japan
6.69%
Switzerland
5.32%
Germany
4.30%
United Kingdom
4.16%
Denmark
3.06%
China
2.20%
Unavailable
0.39%
Other
1.87%
Sectors
Health Care
90.58%
Unavailable
9.42%
Diversification
Total weight of top 15 holdings out of 50
Top 15 holdings
Data as of March 31, 2026
MODERNA INC
ARCELLX
IPSEN PROMESSES
TAKEDA PHARMACEUTICAL
REVOLUTION MEDICINES INC
MERCK & CO INC
BAYER AG
GSK PLC
Create a free account to view top holdings
REGENERON PHARMACEUTICALS
CH1499059983
VERTEX PHARMACEUTICALS
EXELIXIS
SANOFI SA
BIONTECH SE ADR
INCYTE
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
No
SDG

ESG Consensus® by Conser

Data as of February 27, 2026
Methodology

Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about XDNA ETF's sustainability, based on their methodology.

Learn more about Conser

ESG Consensus®
esg grade icon

ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.


XDNA’s has a Final Sustainability Grade of either B+, B, or B-.

This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight Enterprise
Holdings review
83.26% of holdings have positive scoring
17.13% of holdings have negative scoring
10.20%
56.37%
16.70%
10.94%
Consensus levels
Strong
Medium
Weak
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Replication

Trackinsight replication rating:
1-year trailing difference
As of April 30, 2026
Create a free account to view the replication graph
XDNA
N/A
Replication quality
Calculated over 12m, as of April 30, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model

Issuer

iShares
iShares ID Card
Number of funds
1742
Total AuM
€5.19T
Expense ratio range
0.03% - 1.51%
Average expense ratio
0.284%
Top 5 funds by iShares
AuM
IVV
iShares Core S&P 500 ETF€683.8B
IEFA
iShares Core MSCI EAFE ETF€153.41B
IEMG
iShares Core MSCI Emerging Markets ETF€128.92B
CSSPX
iShares Core S&P 500 UCITS ETF€121.01B
IWDA
iShares Core MSCI World UCITS ETF€116.89B

Frequently asked questions about XDNA

What does iShares Genomics Immunology and Healthcare Index ETF, XDNA, invest in?

XDNA is a Passive ETF. This ETF provides exposure to Global Equities.

Which benchmark or index does XDNA replicate?

XDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD, through a optimized sampling replication method.

What is the Total Expense ratio (TER) of XDNA?

XDNA carries a total expense ratio (TER) of 0.44%, indicating the annual cost for holding the fund.

When was XDNA launched?

XDNA was introduced to the market on April 26, 2022. It trades on Canada

Who is the ETF issuer of XDNA?

iShares Genomics Immunology and Healthcare Index ETF, XDNA, is provided by iShares. Learn more about iShares here.

What is the current assets under management (AUM) of XDNA?

XDNA oversees €4.5M in assets as of May 1, 2026.

How has XDNA performed lately?

Based on data from May 1, 2026, XDNA returned -1.53% over the past month, 0.92% over the last three months and 10.98% year-to-date.

What are the latest inflows or outflows for XDNA?

As of May 1, 2026, XDNA recorded net flows of +€681K over the last month and +€681K year-to-date.

Does XDNA distribute dividends?

XDNA follows a distributing dividend policy, meaning it pays out income to investors. As of May 1, 2026, its 12-month trailing yield was 0.39%.

What are the main country or region exposures of XDNA?

As of March 31, 2026, XDNA has significant geographic allocations in USA, France and Japan.

In which sector or theme does XDNA invest in?

As of March 31, 2026, XDNA focuses largely on Health Care.

How many securities does XDNA hold and how diversified is it?

As of March 31, 2026, XDNA holds 50 positions in its portfolio, with 64.07% of assets concentrated in its top 15 holdings.

What are the main positions in XDNA?

As of March 31, 2026, XDNA top three holdings include MODERNA INC, ARCELLX and IPSEN PROMESSES.

What is the base currency of XDNA?

The base currency of XDNA is CAD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight